【摘要】 目的 了解急性白血病（AL）病人凝血酶激活纤溶抑制物（TAFI）活性水平的变化。方法 应用发色底物法检测50例AL病人及30例正常人的TAFI活性水平，并进行统计学比较。结果 AL病人治疗前TAFI：A为2.55±0.84 μg/ml，较正常对照组的7.22±2.22 μg/ml显著降低（P＜0.01）。急性早幼粒细胞白血病（APL）病人TAFI：A为1.50±0.14 μg/ml显著低于其它类型AL（P＜0.05）。结论 AL病人凝血酶激活的纤溶抑制物（TAFI）活性降低，以APL病人表现更显著，但其可随病情好转而逐渐改善。
【关键词】 急性白血病； 凝血酶激活纤溶抑制物
The Clinical Study of Plasma ThrombinActivatable Fibrinolysis Inhibitor in Patients with Acute Leukemia
CHENG Peng，PENG Zhigang，LUO Jun，MA Jie，LUO Lin，LIN Faquan
（The First Affiliated Hospital of Nanning Medical University，Nanning， 530021， China）
Abstract： Objective To explore the significance in the clinical therapy of acute leukemia（AL）.Methods 50 AL patients were selected into the study.The levels of thrombinactivatable fibrinolysis inhibitor ：A were measured by chromogenic assay.Meanwhile，the AL patients were measured before and after therapy.Results Compared with normal group，plasma levels of thrombinactivatable fibrinolysis inhibitor：A were degraded before treatment in AL patients （P＜0.01）.Plasma levels of thrombinactivatable fibrinolysis inhibitor ：A in APL were lower than the other type of acute leukemia.Conclusion Fibrinolysis existed in AL patients and the decrease of antifibrinolysis maybe the main reason of hemorrhage，plasma levels of thrombinactivatable fibrinolysis inhibitor ：A were more lower than the other type of AL.After treatment，plasma levels of thrombinactivatable fibrinolysis inhibitor ：A came to recovery.
Key words： Acute leukemia； Thrombinactivatable fibrinolysis inhibitor
凝血酶激活纤溶抑制物（thrombinactivatable fibrinolysis inhibitor，TAFI）是近年来发现的一种新的凝血和纤溶调控因子。TAFI属金属羧肽酶，血液凝固时，TAFI被凝血酶凝血酶调节蛋白复合物（TTM复合物）激活后，可特异性裂解纤维蛋白或其分子片段C末端的赖氨酸残基，从部分降解的纤维蛋白上移除，使纤溶酶原结合位点减少，干扰纤溶酶原与纤维蛋白基质的结合，下调纤溶活性，对纤维蛋白溶解有抑制作用[1]。
&n
[1] [2] [3] [4] [5] 下一页
您现在的位置： 绿色健康网 >> 医学论文 >> 临床医学论文 >> 正文